RxDoctor Payments Data

Vandana Mathur

Nephrology · Woodside, CANPI 1699078915

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $769,375 of the $769,375 with a category attached, or 100.0%. Myovant Sciences Inc. accounts for 92.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $407,813 and has fallen 99.1% since, to $3,500 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$769,375in general payments, 2019–2025

Across 49 payments — averaging $15,702 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$714K
  • Biogen$53K
  • Sumitomo Pharma America, Inc.$2K

What the payments were for

  • Consulting fees$769,375100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Myovant Sciences Inc.37$714,488
Biogen7$52,750
Sumitomo Pharma America, Inc.5$2,138

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769,375 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Other nephrology in Woodside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →